Company Overview of Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism in the United States. The company’s product candidates include AG-221, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein for the treatment of patients with cancers that harbor IDH2 mutations; and AG-120, an oral inhibitor of the mutated IDH1 protein for the treatment of patients with cancers that harbor IDH1 mutations. Its product candidates also comprise AG-348, an oral small molecule and activator of the pyruvate kinase-R enzyme used for the treatment of patients with PK...
38 Sidney Street
Cambridge, MA 02139
Founded in 2007
Key Executives for Agios Pharmaceuticals, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $425.0K
Principal Financial Officer, Principal Accounting Officer and Senior Vice President of Finance
Total Annual Compensation: $269.1K
Chief Operating Officer
Total Annual Compensation: $350.0K
Chief Scientific Officer
Total Annual Compensation: $376.0K
Compensation as of Fiscal Year 2013.
Agios Pharmaceuticals, Inc. Key Developments
Agios Pharmaceuticals Inc. Announces Collaboration with Celgene Corp. to Initiate Clinical Development of AG-881 in the Second Quarter of 2015
Apr 30 15
Agios Pharmaceuticals Inc. in collaboration with its cancer metabolism partner Celgene Corp. plans to initiate clinical development of AG-881 in the second quarter of 2015. AG-881 will be the third IDH, or isocitrate dehydrogenase, mutant inhibitor discovered by Agios to enter clinical development. Under the terms of the new AG-881 collaboration, Agios will receive an initial payment of $10 million from Celgene in the second quarter of 2015 and is eligible to receive regulatory milestone payments of up to $70 million.
United States Food and Drug Administration Grants Agios Pharmaceuticals, Inc.'s Orphan Drug Designation for its Investigational Medicine AG-348
Mar 24 15
Agios Pharmaceuticals, Inc. announced that the United States Food and Drug Administration (FDA) has granted the company orphan drug designation for its investigational medicine AG-348 for the treatment of pyruvate kinase (PK) deficiency, a rare form of hemolytic anemia. AG-348, a first-in-class, orally available activator of pyruvate kinase-R (PKR) enzymes, met its primary endpoints in two Phase 1 healthy volunteer studies 'a single ascending dose study and multiple ascending dose study. In addition, data presented in December 2014 at the 54th Annual Meeting of the American Society of Hematology (ASH) provided early proof-of-mechanism for AG-348. Based on these findings, Agios plans to initiate a Phase 2 clinical trial in patients with PK deficiency in the first half of 2015. Based on findings presented at ASH, Agios expects to initiate a Phase 2 study of AG-348 in patients with PK deficiency in the first half of 2015. The company plans to provide final results from the Phase 1 multiple ascending dose study at a medical conference in mid-2015. A natural history study of PK deficiency is also ongoing and Agios expects to report initial data from this study at a medical conference in mid-2015.
Kevin Starr, a Board of Director of Agios Pharmaceuticals, Inc. Not to Stand for Re-Election at its 2015 Annual Meeting of Stockholders
Mar 13 15
On March 10, 2015, Kevin Starr notified Agios Pharmaceuticals, Inc. of his decision not to stand for re-election to the Board of Directors at the company when his current term expires at the company's 2015 annual meeting of stockholders. Mr. Starr will continue to serve as the chairman of the Board, a member of the Audit Committee, and the chair of the Nominating and Corporate Governance Committee until the conclusion of the 2015 annual meeting of stockholders.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|